Hsbc Holdings PLC Has $566,000 Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Hsbc Holdings PLC lowered its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 62.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,695 shares of the company's stock after selling 2,805 shares during the quarter. Hsbc Holdings PLC's holdings in Medpace were worth $566,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Medpace by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company's stock valued at $854,087,000 after purchasing an additional 25,704 shares in the last quarter. Invesco Ltd. increased its position in Medpace by 91.8% during the fourth quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock worth $360,387,000 after buying an additional 519,186 shares in the last quarter. Wasatch Advisors LP raised its stake in Medpace by 3.1% in the 4th quarter. Wasatch Advisors LP now owns 936,842 shares of the company's stock valued at $311,247,000 after purchasing an additional 28,161 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Medpace by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 656,130 shares of the company's stock valued at $218,031,000 after buying an additional 28,076 shares during the period. Finally, Bessemer Group Inc. increased its position in Medpace by 15.0% during the fourth quarter. Bessemer Group Inc. now owns 576,044 shares of the company's stock worth $191,379,000 after purchasing an additional 75,275 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on MEDP shares. TD Cowen downgraded shares of Medpace from a "buy" rating to a "hold" rating and dropped their price target for the stock from $370.00 to $328.00 in a research note on Monday, April 14th. Mizuho dropped their price target on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research note on Monday, March 24th. William Blair restated a "market perform" rating on shares of Medpace in a research report on Tuesday, April 22nd. Finally, Robert W. Baird cut their target price on Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 23rd. Eleven analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $349.30.

Insider Transactions at Medpace

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the sale, the director now owns 2,998 shares of the company's stock, valued at $904,856.36. This trade represents a 36.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 20.30% of the stock is currently owned by insiders.

Medpace Price Performance

MEDP stock traded up $7.02 during midday trading on Monday, hitting $303.05. The company's stock had a trading volume of 36,295 shares, compared to its average volume of 345,656. The company's fifty day moving average price is $306.90 and its 200 day moving average price is $328.59. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $459.77. The stock has a market capitalization of $8.71 billion, a P/E ratio of 24.21, a PEG ratio of 3.81 and a beta of 1.55.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.06 by $0.61. The firm had revenue of $558.57 million for the quarter, compared to analyst estimates of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same quarter in the prior year, the company earned $3.20 earnings per share. Equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.